Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000800465 | SCV000940183 | pathogenic | Spastic paraplegia | 2023-09-21 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Asp1903Tyrfs*31) in the SACS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 2677 amino acid(s) of the SACS protein. This variant is not present in population databases (gnomAD no frequency). For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the SACS protein in which other variant(s) (p.3903*, p.Lys2931Asnfs*22, p.Ile2949Phefs*4) have been determined to be pathogenic (PMID: 10655055, 11788093, 15486997, 19892370, 21745802). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. Experimental studies and prediction algorithms are not available or were not evaluated, and the functional significance of this variant is currently unknown. ClinVar contains an entry for this variant (Variation ID: 646225). This variant has not been reported in the literature in individuals affected with SACS-related conditions. |
Baylor Genetics | RCV003472362 | SCV004202288 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2022-09-17 | criteria provided, single submitter | clinical testing |